const fs = require('fs');
const path = require('path');
const dir = __dirname;

function buildPost(p) {
  const sectionsHTML = p.sections.map(s =>
    `\n                <h2>${s.h2}</h2>\n                ${s.content}`
  ).join('\n');
  const relatedHTML = p.related.map(r =>
    `                    <a href="${r.href}" class="related-card">\n                        <span class="post-category">${r.cat}</span>\n                        <h4>${r.title}</h4>\n                    </a>`
  ).join('\n');
  return `<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <link rel="icon" type="image/png" href="favicon.png">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>${p.title} - Sensa Wellness</title>
    <meta name="description" content="${p.desc}">
    <meta name="theme-color" content="#1800AD">
    <link rel="canonical" href="https://www.sensawellness.org/post-${p.slug}.html">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://www.sensawellness.org/post-${p.slug}.html">
    <meta property="og:title" content="${p.title} - Sensa Wellness">
    <meta property="og:description" content="${p.desc}">
    <meta property="og:image" content="https://www.sensawellness.org/sensa-og.jpg">
    <meta name="twitter:card" content="summary_large_image">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Nunito:wght@300;400;700&family=Quicksand:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="styles.css">
    <link rel="stylesheet" href="theme.css">
    <style>
        .wellness-disclaimer { font-size: 0.72rem; color: rgba(255,255,255,0.5); max-width: 800px; margin: 0 auto 1rem; line-height: 1.5; text-align: center; }
    </style>
</head>
<body>

    <div class="progress-bar" id="progressBar"></div>

    <header>
        <div class="header-inner">
            <a href="/" class="logo">
                <img src="logo.jpg" alt="Sensa" class="logo-img">
            </a>
            <button class="mobile-toggle" id="mobileToggle" aria-label="Toggle menu">
                <span></span>
                <span></span>
                <span></span>
            </button>
            <nav id="mainNav">
                <a href="/">Home</a>
                <a href="/#about">About</a>
                <a href="/blog" class="nav-active">Blog</a>
                <a href="/app">App</a>
                <a href="/#team">Team</a>
                <a href="/pay-now" class="btn">Buy Now</a>
            </nav>
        </div>
    </header>

    <article class="post">
        <div class="post-header-section">
            <div class="container post-container">
                <a href="/blog" class="back-link">&larr; Back to Blog</a>
                <div class="post-meta">
                    <span class="post-category">${p.category}</span>
                    <span class="post-date">${p.dateDisplay}</span>
                    <span class="post-read">${p.readTime}</span>
                </div>
                <h1>${p.title}</h1>
                <p class="post-subtitle">${p.subtitle}</p>
            </div>
        </div>

        <div class="container post-container">
            <div class="post-body">

                ${p.intro}
${sectionsHTML}

                <div class="post-cta">
                    <h3>${p.ctaH3}</h3>
                    <p>${p.ctaP}</p>
                    <a href="/pay-now" class="btn">Buy Now</a>
                </div>
            </div>

            <div class="blog-newsletter">
                <h3>Get inflammation insights in your inbox</h3>
                <p>New articles on inflammation science, plus updates on the Sensa at-home CRP test and app.</p>
                <form class="newsletter-form" id="postNewsletterForm">
                    <input type="email" id="postNewsletterEmail" placeholder="Your email address" required>
                    <button type="submit" class="btn">Subscribe</button>
                </form>
                <span class="newsletter-note">No spam. Unsubscribe anytime.</span>
            </div>
            <script>
                document.getElementById('postNewsletterForm').addEventListener('submit', function(e) {
                    e.preventDefault();
                    var email = document.getElementById('postNewsletterEmail').value.trim();
                    if (!/^[^\\s@]+@[^\\s@]+\\.[^\\s@]+$/.test(email)) return;
                    var btn = e.target.querySelector('button[type="submit"]');
                    btn.textContent = 'Submitting\\u2026';
                    btn.disabled = true;
                    fetch('https://script.google.com/macros/s/AKfycbyQVIxWJrJNYp0KgEMAeF-pfCpGJPmS3w3O4enN_Dv_KITjfjfl5qeZB9uEMAnJ7CWc_g/exec', {
                        method: 'POST',
                        mode: 'no-cors',
                        headers: { 'Content-Type': 'application/json' },
                        body: JSON.stringify({ name: '', email: email, interest: 'newsletter', source: 'blog-post:' + location.pathname })
                    }).finally(function() {
                        btn.textContent = 'Subscribed!';
                        btn.style.background = '#41a6f0';
                        e.target.reset();
                    });
                });
            </script>

            <div class="related-posts">
                <h3>Related Articles</h3>
                <div class="related-grid">
${relatedHTML}
                </div>
            </div>
        </div>
    </article>

    <footer>
        <div class="container">
            <div class="footer-grid">
                <div class="footer-brand">
                    <h3>Sensa Wellness</h3>
                    <p>Sensa Wellness is on a mission to make inflammation monitoring as simple as brushing your teeth. Because understanding what's happening inside your body shouldn't require a lab visit.</p>
                </div>
                <div class="footer-links">
                    <h4>Quick Links</h4>
                    <ul>
                        <li><a href="/">Home</a></li>
                        <li><a href="/#about">About</a></li>
                        <li><a href="/blog">Blog</a></li>
                        <li><a href="/pay-now">Buy Now</a></li>
                        <li><a href="/work-with-us">Work With Us</a></li>
                        <li><a href="/editorial-standards">Editorial Standards</a></li>
                    </ul>
                </div>
                <div class="footer-links">
                    <h4>Solutions</h4>
                    <ul>
                        <li><a href="#">Inflammation Monitoring</a></li>
                        <li><a href="#">Preventive Screening</a></li>
                        <li><a href="/app">Mobile Integration</a></li>
                        <li><a href="#">Community Programs</a></li>
                        <li><a href="#">Corporate Wellness</a></li>
                    </ul>
                </div>
                <div class="footer-links">
                    <h4>Contact</h4>
                    <div class="footer-contact-item">
                        sensawellness@gmail.com
                    </div>
                    <div class="social-links">
                        <a href="#" class="social-link" aria-label="Instagram">IG</a>
                        <a href="#" class="social-link" aria-label="LinkedIn">in</a>
                    </div>
                </div>
            </div>
            <div class="footer-bottom">
                <p class="wellness-disclaimer">Sensa is a general wellness product intended to support a healthy lifestyle. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Results are not a substitute for professional medical advice, diagnosis, or treatment. If you have concerns about your health, consult a qualified healthcare provider.</p>
                &copy; 2026 Sensa Wellness. All Rights Reserved.
            </div>
        </div>
    </footer>

    <button class="scroll-top" id="scrollTop" aria-label="Scroll to top">Top</button>

    <script>
        window.addEventListener('scroll', () => {
            const scrollTop = document.documentElement.scrollTop;
            const scrollHeight = document.documentElement.scrollHeight - document.documentElement.clientHeight;
            document.getElementById('progressBar').style.width = (scrollTop / scrollHeight) * 100 + '%';
            const btn = document.getElementById('scrollTop');
            if (scrollTop > 400) { btn.classList.add('visible'); } else { btn.classList.remove('visible'); }
        });
        document.getElementById('scrollTop').addEventListener('click', () => { window.scrollTo({ top: 0, behavior: 'smooth' }); });
        document.getElementById('mobileToggle').addEventListener('click', () => { document.getElementById('mainNav').classList.toggle('active'); });
        document.querySelectorAll('#mainNav a').forEach(link => { link.addEventListener('click', () => { document.getElementById('mainNav').classList.remove('active'); }); });
    </script>

<script src="theme-fx.js" defer></script>
</body>
</html>`;
}

const posts = [

  // Aug 27 -- Evergreen Science: Magnesium deficiency and inflammation / CRP
  {
    slug: 'magnesium-inflammation',
    title: 'Magnesium Deficiency and Inflammation: The Mineral Most People Are Not Getting Enough Of',
    desc: 'Roughly half of Americans fall short of the recommended magnesium intake. Research consistently links low magnesium status to elevated CRP and chronic low-grade inflammation. Here is what the science shows.',
    subtitle: 'Magnesium is a cofactor in over 300 enzymatic reactions, many of them central to immune regulation and inflammatory control. When intake is inadequate — as it is for a large share of the population — the biology of chronic inflammation becomes harder to manage.',
    category: 'Science',
    dateDisplay: 'August 27, 2026',
    readTime: '7 min read',
    intro: `<div class="answer-box">
                    <span class="answer-label">The short answer</span>
                    <p>Low magnesium intake is consistently associated with elevated C-reactive protein across large population studies, and several randomized controlled trials have shown that magnesium supplementation reduces CRP in people who are deficient. The relationship is biologically grounded: magnesium regulates NF-κB (the master inflammatory transcription factor), modulates the calcium signaling that triggers inflammatory cascades, and is required for ATP synthesis and antioxidant production. Roughly half of U.S. adults consume less magnesium than the Estimated Average Requirement. For many people, improving magnesium intake — through diet first, supplementation where needed — may be one of the more overlooked levers for reducing low-grade inflammation.</p>
                </div>

                <p>Magnesium rarely commands the same cultural attention as vitamin D or omega-3s. It does not carry the marketing weight of a trendy supplement. But the evidence connecting magnesium status to systemic inflammation is deep, consistent, and mechanistically well understood — and the prevalence of inadequate intake in the general population makes it a genuinely important topic for anyone thinking seriously about inflammation and long-term health.</p>

                <p>A 2012 analysis published in <em>Nutrition Reviews</em> estimated that approximately 48% of Americans consume less magnesium than the Estimated Average Requirement — and that estimate has held up in subsequent national survey data. This is not a deficiency in the clinical sense of frank hypomagnesemia, but a chronic low-grade insufficiency that operates below the threshold of obvious symptoms while still influencing biochemistry. The connection to inflammation is one of the more actionable findings in nutritional epidemiology: low magnesium intake predicts higher CRP, and correcting that shortfall, at least in people who are insufficient, appears to move inflammatory markers in the right direction.</p>`,
    sections: [
      {
        h2: 'How Magnesium Shapes the Inflammatory Response',
        content: `<p><strong>Magnesium functions as an essential regulator of nuclear factor-kappa B (NF-κB), the transcription factor that controls the expression of dozens of pro-inflammatory genes.</strong> When cells are stressed, infected, or damaged, NF-κB normally activates the immune response — producing cytokines like TNF-alpha, IL-1β, and IL-6 that drive inflammation. Magnesium suppresses NF-κB activation through several mechanisms, including stabilizing inhibitory proteins that keep NF-κB sequestered in the cytoplasm. When magnesium is low, this inhibitory pressure weakens, and NF-κB activity — and downstream inflammatory signaling — increases.</p>

                <p><strong>Magnesium also governs calcium signaling, and calcium is a key second messenger in inflammatory cascades.</strong> Intracellular calcium levels are tightly regulated by magnesium-dependent ion channels and pumps. When magnesium status declines, calcium can accumulate inside cells at higher-than-normal concentrations, activating enzymes and signaling pathways that amplify the inflammatory response. This calcium-magnesium imbalance is one of the primary cellular mechanisms through which magnesium insufficiency translates into heightened inflammatory tone.</p>

                <p><strong>At the mitochondrial level, magnesium is essential for ATP synthesis, and mitochondrial dysfunction under magnesium-insufficient conditions generates reactive oxygen species (ROS).</strong> Oxidative stress from excess ROS is a well-established driver of inflammatory signaling — ROS directly activates NF-κB and promotes the release of inflammatory mediators from immune cells. Magnesium is also required as a cofactor in the production of glutathione, the body's primary endogenous antioxidant. Lower magnesium means lower antioxidant capacity, which means less buffering against oxidative stress and, in turn, more inflammatory signaling. These mechanisms are not theoretical: they are the biochemical basis for the consistent epidemiological association between magnesium intake and CRP.</p>`
      },
      {
        h2: 'How Common Is Inadequate Magnesium Intake — and Why',
        content: `<p><strong>The scale of magnesium insufficiency in modern Western diets is largely a story of food processing.</strong> Magnesium is found in the bran and germ of whole grains — the parts removed during refining. When whole wheat is milled into white flour, approximately 80 to 85% of its magnesium is lost. When brown rice is polished into white rice, a similar fraction disappears. Because refined grains form the structural base of most processed foods, and because ultra-processed foods now account for more than half of caloric intake in the United States, large portions of the population are simply not eating the foods that contain meaningful amounts of magnesium.</p>

                <p><strong>Several factors beyond diet further reduce effective magnesium status.</strong> Proton pump inhibitors (PPIs), one of the most commonly prescribed drug classes in the United States, have been associated with hypomagnesemia through impaired intestinal magnesium absorption. Thiazide and loop diuretics increase urinary magnesium excretion. Chronic alcohol use does the same. High chronic stress elevates urinary magnesium loss through the catecholamine-driven mobilization of intracellular magnesium stores. Gut dysbiosis and intestinal inflammation reduce magnesium absorption in the small intestine. Many of these factors co-occur in the same individuals, compounding their individual effects.</p>

                <p><strong>One complication in assessing magnesium status is that serum magnesium is a poor biomarker of total body stores.</strong> Only about 1% of the body's magnesium is in the blood — the rest is distributed in bones (60%), muscles (27%), and other soft tissues. This means serum magnesium can remain within the reference range even when intracellular and bone stores are depleted. Standard blood panels may not flag a functional magnesium insufficiency, which is one reason why the population-level data on dietary intake is a more informative window into actual magnesium status than individual bloodwork. Erythrocyte (red blood cell) magnesium testing offers a somewhat better picture of intracellular stores, but it is not widely used in routine clinical practice.</p>`
      },
      {
        h2: 'What the Research Shows About Magnesium, CRP, and Supplementation',
        content: `<p><strong>The epidemiological association between magnesium intake and CRP is one of the more replicated findings in nutritional inflammation research.</strong> A landmark 2005 analysis by King and colleagues, drawing on data from 3,713 adults in the National Health and Nutrition Examination Survey (NHANES), found that people in the lowest quartile of magnesium intake had significantly higher CRP levels than those in the highest quartile — an association that persisted after controlling for age, BMI, smoking, physical activity, and other confounders. This type of inverse dose-response relationship has been reproduced in subsequent NHANES analyses and in cohort studies in Europe and Asia.</p>

                <p><strong>Dibaba and colleagues conducted the most comprehensive systematic review and meta-analysis of this relationship, published in the <em>European Journal of Clinical Nutrition</em> in 2014.</strong> Pooling data from eleven observational studies, they found a significant inverse association between dietary magnesium intake and serum CRP — each 100 mg/day increment in magnesium intake was associated with meaningfully lower CRP levels. A second meta-analysis, published in <em>Nutrients</em> in 2019, evaluated randomized controlled trials of magnesium supplementation specifically and found that supplementation significantly reduced serum CRP levels (standardized mean difference: −0.36; 95% CI: −0.62 to −0.10) in people who were magnesium-insufficient, with larger effects in individuals with higher baseline CRP. These are modest but consistent effects — the kind of signal that holds up across independent investigations with different populations and methods.</p>

                <p><strong>The intervention data suggest the relationship is at least partially causal in people who are insufficient.</strong> RCTs showing CRP reduction with magnesium supplementation have enrolled overweight adults, people with type 2 diabetes, and postmenopausal women — populations with higher baseline prevalence of magnesium insufficiency and elevated inflammation. The common thread is baseline insufficiency: the evidence for CRP reduction is strongest in individuals who are not getting adequate magnesium to begin with. In people who are already meeting their needs through diet, adding more magnesium does not appear to produce dramatic further reductions in CRP. This is consistent with the nutritional biology: replenishing a deficiency corrects a dysfunction; adding more beyond sufficiency does not necessarily add more benefit.</p>`
      },
      {
        h2: 'Food Sources, Supplementation, and Tracking Your Baseline',
        content: `<p><strong>The most magnesium-dense foods are ones that appear in anti-inflammatory dietary patterns more broadly.</strong> Pumpkin seeds are among the highest single sources at roughly 168 mg per ounce. Other top sources include hemp seeds, chia seeds, almonds, cashews, black beans, edamame, dark leafy greens (particularly spinach and Swiss chard), dark chocolate (70%+ cacao), avocado, and whole grains including brown rice, oats, and quinoa. Many of these foods also provide fiber, polyphenols, and omega-3 fatty acids — nutrients with their own anti-inflammatory properties — which helps explain why whole-food dietary patterns tend to show the strongest associations with lower CRP in population research. The RDA for magnesium is 400 to 420 mg/day for adult men and 310 to 320 mg/day for adult women, with requirements increasing slightly during pregnancy.</p>

                <p><strong>When dietary intake is genuinely insufficient, supplementation is a practical option — but form matters.</strong> Magnesium oxide is the most common form in supplements and pharmacy products, but it has relatively poor bioavailability (approximately 4%). Magnesium glycinate (magnesium bound to glycine) and magnesium citrate are substantially better absorbed and are generally better tolerated at higher doses. Magnesium malate is another well-absorbed form. For most people, magnesium glycinate at 200 to 400 mg/day is a reasonable starting point when dietary intake is low, though it is worth discussing any supplementation with a healthcare provider, particularly if you take medications that interact with magnesium absorption or if you have kidney disease (the kidneys regulate magnesium excretion, so impaired kidney function changes the calculus significantly).</p>

                <p><strong>One practical value of tracking CRP over time is that it gives you a window into whether dietary and lifestyle changes are actually moving your inflammatory baseline.</strong> Magnesium is one piece of that picture — along with sleep quality, physical activity, body composition, omega-3 intake, fiber consumption, and stress management, all of which influence inflammatory tone through overlapping and sometimes independent pathways. Because CRP reflects the net output of all those inputs, longitudinal monitoring can help you distinguish signal from noise: a few weeks of improved diet can show up in your CRP numbers, and that data is more informative than any single dietary assessment. It is also the kind of concrete, personalized information worth sharing with a healthcare provider when you are thinking about your long-term health.</p>`
      }
    ],
    ctaH3: 'See how your diet and lifestyle move your CRP',
    ctaP: 'Sensa is a general wellness at-home CRP test designed for longitudinal monitoring. Track how changes in nutrition, sleep, and activity influence your inflammatory baseline — and bring real data to your next healthcare conversation. Not a diagnostic, just your own biology, made visible.',
    related: [
      { href: '/post-vitamin-d-inflammation', cat: 'Science', title: 'Vitamin D and Inflammation: The Deficiency Most People Do Not Know They Have' },
      { href: '/post-omega3-inflammation', cat: 'Lifestyle', title: 'Do Omega-3s Reduce Inflammation?' },
      { href: '/post-fiber-inflammation', cat: 'Lifestyle', title: 'Dietary Fiber and Inflammation: Why Your Gut Bacteria Need You to Eat More Plants' }
    ]
  },

  {
    slug: 'zeus-trial-crp-inflammation',
    title: 'When Lowering CRP Wasn\'t Enough: What the ZEUS Trial Tells Us About Inflammation',
    desc: 'A major Phase 3 trial showed that an IL-6 inhibitor sharply reduced CRP — but did not prevent heart attacks or strokes. Here is what the null result means for inflammation science and CRP monitoring.',
    subtitle: 'On July 31, 2026, Novo Nordisk announced that ziltivekimab — a drug that reliably lowers IL-6 and hsCRP — failed to reduce cardiovascular events in over 6,300 high-risk patients. The finding is complicated, and it matters.',
    category: 'News',
    dateDisplay: 'August 26, 2026',
    readTime: '8 min read',
    intro: `<div class="answer-box">
                    <span class="answer-label">The short answer</span>
                    <p>The ZEUS Phase 3 trial found that ziltivekimab, an IL-6 inhibitor, significantly reduced hsCRP and free IL-6 in patients with cardiovascular disease, chronic kidney disease, and elevated inflammation — but produced no reduction in heart attacks, strokes, or cardiovascular death (HR 0.99). The null result does not mean CRP is an unreliable biomarker. It means that pharmacologically suppressing one inflammatory signaling pathway is more complicated than it sounds, and that understanding what drives your own CRP — through lifestyle, metabolic health, and longitudinal monitoring — may matter more than any single intervention.</p>
                </div>

                <p>For years, one of medicine's most tantalizing hypotheses has been this: if inflammation is a major driver of cardiovascular disease, and if we can suppress inflammation with a drug, we should be able to prevent heart attacks and strokes. The logic is straightforward. The evidence linking elevated C-reactive protein (CRP) to cardiovascular risk is extensive and well-replicated. Therapies that target the inflammatory cascade have shown promise in both laboratory settings and earlier trials. The question was whether a highly specific anti-inflammatory biologic — designed precisely to interrupt the IL-6 signaling pathway that drives CRP production — could translate that biological logic into clinical outcomes.</p>

                <p>On July 31, 2026, Novo Nordisk announced that it could not — at least not in the ZEUS trial. <a href="https://www.globenewswire.com/news-release/2026/07/31/3336733/0/en/novo-nordisk-provides-update-on-the-zeus-phase-3-trial-in-people-with-ascvd-ckd-and-inflammation.html" target="_blank" rel="noopener">The topline results from ZEUS</a>, a Phase 3 cardiovascular outcomes trial of ziltivekimab in over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated hsCRP, showed no reduction in major adverse cardiovascular events (MACE). The hazard ratio was 0.99 — effectively identical outcomes between the treatment and placebo arms. The drug did exactly what it was designed to do biologically. It just did not do what patients and researchers hoped it would do clinically.</p>`,
    sections: [
      {
        h2: 'What the ZEUS Trial Was Designed to Prove',
        content: `<p><strong>The scientific rationale behind ZEUS was built on decades of observational and mechanistic research.</strong> CRP and its upstream regulator interleukin-6 (IL-6) are established markers of systemic inflammation. IL-6 is a cytokine produced by immune cells and adipose tissue in response to stress, infection, and chronic low-grade inflammation; it signals the liver to produce acute-phase proteins, most notably CRP. Elevated hsCRP — particularly above 2 mg/L — has been consistently associated with increased risk of heart attack, stroke, and cardiovascular mortality in large prospective studies, even after controlling for LDL cholesterol, blood pressure, and other traditional risk factors.</p>

                <p><strong>Ziltivekimab is a highly specific inhibitor of the IL-6 ligand</strong>, meaning it binds to IL-6 itself before it can activate its receptor, blocking the downstream signal that tells the liver to raise CRP. The drug had already demonstrated strong biological activity in earlier studies: in the RESCUE trial (2021), ziltivekimab dramatically reduced hsCRP, fibrinogen, serum amyloid A, and other inflammatory markers in patients with chronic kidney disease and elevated inflammation — exactly the population enrolled in ZEUS. The biological mechanism was sound. The question was whether that biological effect translated into fewer cardiovascular events.</p>

                <p><strong>The trial was large and carefully designed.</strong> ZEUS enrolled more than 6,300 participants with ASCVD, CKD (estimated glomerular filtration rate between 15 and 59 mL/min/1.73m&#178;), and hsCRP &#8805;2 mg/L. Participants received either ziltivekimab 15 mg once monthly or placebo on top of standard-of-care therapy. The primary outcome was MACE: a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. It was one of the most rigorously designed anti-inflammatory cardiovascular outcomes trials ever conducted, and it was anticipated to provide a definitive answer to whether IL-6 pathway inhibition could protect the heart.</p>`
      },
      {
        h2: 'The Results: CRP Fell. Heart Attacks Did Not.',
        content: `<p><strong>The drug delivered on its biological promise.</strong> Ziltivekimab produced the expected, significant reductions in free IL-6 and hsCRP in treated patients. Target engagement was confirmed. Biologically, the drug did exactly what its designers intended: it interrupted the IL-6 signaling pathway and measurably suppressed the downstream inflammatory response captured by CRP. From a pure pharmacology standpoint, the drug worked.</p>

                <p><strong>But the clinical outcome was flat.</strong> <a href="https://www.hcplive.com/view/ziltivekimab-fails-to-reduce-mace-risk-in-phase-3-zeus-trial" target="_blank" rel="noopener">According to topline results released July 31, 2026</a>, the hazard ratio for MACE was 0.99 (95% CI: 0.88&#8211;1.11) — a precision null result. There was no statistically significant difference in cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke between patients who received ziltivekimab and those who received placebo. In a trial of more than 6,300 participants with this level of follow-up, a null result is not ambiguous. It means the intervention, in this population, did not produce the hoped-for cardiovascular protection despite measurably lowering a validated inflammatory biomarker.</p>

                <p><strong>Safety signals added another layer of nuance.</strong> Serious infections were more frequent in the ziltivekimab arm than in the placebo arm — a finding consistent with the known biology of IL-6 pathway blockade. IL-6 plays an important role in the acute immune response to infection, and suppressing it can blunt the body's ability to mount that response quickly. This is a class effect seen with other IL-6 pathway inhibitors like tocilizumab. Full safety data will be presented at an upcoming scientific meeting, and two additional ziltivekimab trials — HERMES (in heart failure patients) and ARTEMIS (post-acute MI) — remain ongoing, with readouts expected in early 2027.</p>`
      },
      {
        h2: 'What This Tells Us About CRP, IL-6, and the Inflammation Hypothesis',
        content: `<p><strong>The ZEUS result does not mean CRP is an unreliable marker of cardiovascular risk.</strong> The observational evidence linking elevated hsCRP to cardiovascular events is extensive and replicates consistently across hundreds of studies in diverse populations. The 2025 ACC Scientific Statement on Inflammation and Cardiovascular Disease, published in the <em>Journal of the American College of Cardiology</em>, concluded that "the evidence linking inflammation with ASCVD is no longer exploratory but is compelling and clinically actionable." That foundation did not shift with the ZEUS trial. Elevated hsCRP still predicts residual cardiovascular risk, particularly in patients whose LDL is already managed by statins.</p>

                <p><strong>What the ZEUS result suggests is that reducing CRP pharmacologically does not automatically protect the cardiovascular system.</strong> The contrast with earlier trials is instructive. In the CANTOS trial (2017), canakinumab — an antibody targeting IL-1&#946;, the cytokine upstream of IL-6 in the same inflammatory cascade — reduced MACE by 15% (HR 0.85) in post-myocardial infarction patients with elevated hsCRP. Both canakinumab and ziltivekimab lower CRP through the same pathway. Both are antibodies. One was positive; one was not. Similarly, colchicine — which acts further upstream, on the NLRP3 inflammasome — reduced cardiovascular events in both the COLCOT and LoDoCo2 trials. The pattern suggests that <em>where</em> you intervene in the inflammatory cascade matters, and that IL-6 inhibition specifically, at least in the CKD-heavy population enrolled in ZEUS, may not be the right lever.</p>

                <p><strong>The chronic kidney disease population enrolled in ZEUS may also be a critical variable.</strong> Patients with significant kidney disease have altered inflammatory profiles driven by uremic toxins, oxidative stress, altered gut microbiome, and reduced clearance of inflammatory mediators — all of which can sustain CRP elevation through multiple simultaneous pathways. Blocking one of those pathways (IL-6) may be insufficient when several others are still operating. The ZEUS trial was explicitly designed to test IL-6 inhibition in this high-need population. The answer, for now, appears to be that it does not produce a measurable clinical benefit in this context — though the two ongoing trials in different patient populations (HERMES, ARTEMIS) may tell a different story.</p>`
      },
      {
        h2: 'What This Means for Monitoring Your Own Inflammation',
        content: `<p><strong>The complexity of the ZEUS result is actually an argument for understanding your own inflammatory picture more clearly, not less.</strong> If chronic inflammation is multifactorial — driven by diet, adipose tissue activity, stress, poor sleep, dysbiosis, and metabolic dysfunction, among other inputs — then addressing it requires more than suppressing one signaling molecule pharmacologically. It requires identifying what is driving your particular inflammatory state and making changes that address those drivers. That is not something a single biologic can do. It is something that consistent lifestyle modification, tracked over time, can begin to accomplish.</p>

                <p><strong>CRP remains a meaningful signal of what is happening inside your body.</strong> An elevated hsCRP in an otherwise healthy person still indicates that something is generating chronic low-grade inflammation — and that information is still actionable. It is a prompt to examine sleep quality, dietary patterns, physical activity, body composition, stress load, and any symptoms worth discussing with a healthcare provider. The ZEUS trial did not change any of that. What it demonstrated, specifically, is that pharmacologically suppressing one downstream marker of inflammation — without addressing the upstream drivers — may not be sufficient to change hard cardiovascular outcomes. For most people outside a clinical trial, the relevant implication is not "find a pill that lowers CRP" but "understand why CRP is elevated and make the changes that address those reasons."</p>

                <p><strong>Sensa is a general wellness tool for that kind of longitudinal self-monitoring.</strong> Tracking your hsCRP over time — alongside the lifestyle changes you are making — gives you real data on whether those changes are moving your inflammatory baseline in the right direction. It does not replace a cardiovascular risk assessment by a clinician, and it does not diagnose or treat any condition. But in a period when inflammation research is moving fast and the picture is becoming more nuanced, having a sense of your own CRP trend is useful data to bring to those conversations. The ZEUS trial is a reminder that inflammation is complicated. Monitoring it is still worthwhile — and the scientific complexity is exactly why paying attention to your own numbers, over time, matters.</p>`
      }
    ],
    ctaH3: 'Track your inflammatory baseline over time',
    ctaP: 'Sensa is a general wellness at-home CRP test designed for longitudinal monitoring. See how lifestyle changes move your numbers — and bring real data to your next healthcare conversation. Not a diagnostic, just your own biology, made visible.',
    related: [
      { href: '/post-inflammation-modifiable-heart-risk', cat: 'News', title: 'Inflammation Joins the Short List of Modifiable Heart Risk Factors' },
      { href: '/post-crp-heart-attack-risk', cat: 'Science', title: 'CRP and Heart Attack Risk: What Your Inflammation Number Predicts' },
      { href: '/post-heart-disease-inflammation', cat: 'Conditions', title: 'How Does Inflammation Drive Heart Disease?' }
    ]
  }

];

posts.forEach(p => {
  const filePath = path.join(dir, `post-${p.slug}.html`);
  fs.writeFileSync(filePath, buildPost(p));
  console.log(`Written: post-${p.slug}.html`);
});

console.log(`\nDone. ${posts.length} files written.`);
